DOCSLIB.ORG

2018 BMES MOBILE THURSDAY Annual Meeting Platform Sessions Th-1 APP (Thursday 8:00-9:30Am)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2018 BMES MOBILE THURSDAY Annual Meeting Platform Sessions Th-1 APP (Thursday 8:00-9:30Am) TABLE OF CONTENTS TABLE SCIENTIFIC PROGRAM 2018 BMES MOBILE THURSDAY Annual Meeting Platform Sessions Th-1 APP (Thursday 8:00-9:30am) ....................................... 4–13 Go to the Apple or Android Store and search for: Platform Sessions Th-2 BMES (Thursday 1:30-3:00pm) ....................................14–22 Download the Free App > Select BMES2018 Platform Sessions Th-3 (Thursday 3:45-5:15pm) ....................................23–31 Poster Sessions–Thursday ..............................32–91 Browse the program by date or session type FRIDAY Platform Sessions Fri-1 keywords Search (Friday 8:00-9:30am) ....................................... 93–101 Search Author list Platform Sessions Fri-2 Add presentations to (Friday 1:15-2:45pm) .................................. 102–110 a custom itinerary Platform Sessions Fri-3 Click a link to show (Friday 3:30-5:00pm) .................................... where a presentation 111–119 is on the map of the convention center Poster Sessions–Friday .............................. 120–179 SATURDAY Platform Sessions Sat-1 (Saturday 8:00am-9:30am) .........................180–189 Platform Sessions Sat-2 Don't forget to turn your BMES (Saturday 1:30-3:00pm) ............................... 190–198 BASH ticket in for a wristband at Platform Sessions Sat-3 (Saturday 3:15-4:45pm) ...............................199–205 the information or registration Poster Sessions–Saturday ....................... 206–249 booths before Friday afternoon Omni Hotel Floorplan ........................................... 250 Georgia World Congress AUTHOR INDEX Center Floorplan ..................................................... 251 Available on the Mobile App (see ad above) at: http://submissions.mirasmart.com/bmes2018/itinerary Program-at-a-Glance .................................252–257 Copies are also available at the Registration Desk. Schedule-at-a-Glance ............................... 258–260 Atlanta | BMES 2018 1 PROGRAM 2018 PROGRAM 2 BMES 2018 | Atlanta SESSIONS—THURSDAY'S SCHEDULE HIGHLIGHTS SCHEDULE SESSIONS—THURSDAY'S THURSDAY'S SCHEDULE HIGHLIGHTS PLATFORM SESSIONS–THURS–1 INDUSTRY SESSION 8:00 am—9:30 am Convention Center 1:15 pm—3:15 pm Room A402 19 Concurrent Sessions See pages 4—13 Entrepreneur Workshop SPECIAL SESSIONS PLATFORM SESSIONS–THURS–2 8:00 am—9:30 am Georgia State Room 1:30 pm—3:00 pm Convention Center 50th Anniversary Jeopardy 20 Concurrent Sessions See pages 14—22 8:00 am—9:30 am Room A301 STUDENT & EARLY CAREER The Future of Bioelectronics: Materials Processes and Applications 1:30 pm—2:45 pm Room A412A BME Careers in Industry I 8:00 am—9:30 am Room A411 State-of-the-Art ImmunoEngineering 2:30 pm—4:00 pm Exhibit Hall A, and Future Opportunities Rapid Resume Review— Career Zone Members Only 8:00 am—9:30 am Room A310 Single Cell Analysis and Tumor Heterogeneity 3:00 pm—4:00 pm Room A412A BME Careers in Academia INDUSTRY SESSION 4:15 pm—5:15 pm Room A412A 8:00 am—10:00 am Room A402 BME Careers in Industry II Tech Transfer Innovation Challenge SPECIAL SESSIONS STUDENT & EARLY CAREER 1:30 pm—3:00 pm A301 9:00 am—10:00 am Room A412A NIH Funding Panel Session Marketing Yourself: Tips for a Successful Job Search 1:30 pm—3:00 pm A310 Soft Material–Enabled Electronics for Exhibit Hall & Posters Open Medicine, Healthcare and Human– 9:30 am—5:00 pm Exhibit Hall Machine Interfaces Poster Viewing with Authors 2:30 pm—5:00 pm A411 6th US-Korea Joint BMES Workshop on 9:30 am—10:15 am Exhibit Hall Biomedical Engineering 3:00 pm—3:45 pm PLATFORM SESSIONS–THURS–3 PLENARY SESSION 3:45 pm—5:15 pm Convention Center 10:15 am—11:30 am Sidney Marcus Aud. 20 Concurrent Sessions See pages 23—31 State of the Society SPECIAL SESSIONS Lori Setton, PhD BMES President 3:45 pm—5:15 pm Room A310 Novel Photoacoustic Imaging: Systems, Computation and Agents 3:45 pm—5:15 pm Room A301 NIBIB DEBUT Presentations and Awards PLENARY SESSION Rashid Bashir, PhD Pritzker Distinguished Lecture 5:30 pm—6:30 pm Sidney Marcus Department of Bioengineering Auditorium University of Illinois Diversity Award Lecture Anjelica L. Gonzalez, PhD School of Engineering and Applied Science, Yale University & BMES Fellows Celebration of Minorities in BME Luncheon (ticket purchase required) 11:45 am—1:15 pm Room A411 Paula Hammond, PhD Koch Institute for Integrative Industry Mixer Cancer Research, Massachusetts Institute of Technology 7:00 pm—8:30 pm STATS Brewpub (Ticket Purchase Required) (ticket purchase required) HOSTED RECEPTIONS 8:00 pm—10:00 pm Omni Hotel 2 BMES 2018 | Atlanta Atlanta | BMES 2018 3 PLATFORM SESSIONS—THURSDAY—1—8:00 AM—9:30 AM AM—9:30 SESSIONS—THURSDAY—1—8:00 PLATFORM Thursday, October 18 | 8:00 am—9:30 am | Platform Session 1 OP–Thurs–1–1 Room A311 8:15 am—8:30 am 3D Bioprinting Human Adenocarcinoma Cells Track: Biomaterials to Study Epithelial-Mesenchymal Transition Helen Warner1, Mohammad Azimi1, Taylor Scipione1, Hydrogels I Suzanne Lightsey1, Hamzah Shariff1, Kelsey Leong1, Kyle Lampe1, Chairs: Laura Suggs, Nicole Iverson Shayn Peirce1, and Matthew Lazzara1 1University of Virginia, Charlottesville, VA 8:00 am—8:30 am Hydrogels to Promote 8:30 am—8:45 am Endogenous Repair Bioprinted 3D Breast Epithelial Spheroids are Tatiana Segura1 1 More Resistant to Paclitaxel than Single Cells Duke University, Durham, NC Swathi Swaminathan1, Qudus Hamid1, Wei Sun1, and Alisa Clyne1 1 8:30 am—8:45 am Drexel University, Philadelphia, PA Peptide Amphiphile-Hyaluronic Acid 8:45 am—9:00 am Composites for Cartilage Regeneration 3D Printing of Microstructured Collagen in a Large-Animal Model 1 2 3 2 2 Scaffolds to Guide 3D Muscle Organization Jacob Lewis , Brett Nemke , Mark McClendon , Yan Lu , Mark Markel , 1 1 1 1 1 Andrew Lee , Thomas Hinton , Andrew Hudson , Jacqueline Bliley , and Samuel Stupp 1 1 2 and Adam Feinberg Northwestern University, Evanston, IL, University of Wisconsin– 1 Madison, Madison, WI, 3Northwestern University, Chicago, IL Carnegie Mellon University, Pittsburgh, PA 8:45 am—9:00 am 9:00 am—9:15 am Sliding Hydrogels with Tunable Molecular SuperFast 3D Printing of Human-Scale Mobility and Ligands as 3D Niche for Vascularized Tissue Accelerating MSC-based Cartilage Regeneration Nanditha Anandakrishnan1, Hang Ye1, Chi Zhou1, and Ruogang Zhao1 Xinming Tong1 and Fan Yang1 1University at Buffalo, Buffalo, NY 1Stanford University, Stanford, CA 9:15 am—9:30 am 9:00 am—9:15 am Orthogonal Programming of Heterogeneous Chronic Low-rate Contractile Activity and Micro-Mechano-Environments and Geometries Thyroid Hormone Supplementation Enhance in 3D Bio-Stereolithography Structural and Functional Maturation of Yonghui Ding1, Hang Yin1, Xiaobo Yin1, and Wei Tan1 Engineered Rat Myocardium 1University of Colorado at Boulder, Boulder, CO Hanjun Li1, Christopher Jackman1, and Nenad Bursac1 1Duke University, Durham, NC OP–Thurs–1–3 Room A410 9:15 am—9:30 am PEGylated Laminin Hydrogels for Skeletal Track: Cancer Technologies Muscle Regeneration Natalia Ziemkiewicz1, Muhamed Talovic1, Lindsay Hill1, Robert Microfluidic and Microscale Cancer Models 1 1 1 1 Scheidt , Josh Madsen , Anjali Patel , Gabe Haas , Madison Chairs: Steve George, Luis Solorio Marcinczyk1, Silviya Zustiak1, and Koyal Garg1 1Saint Louis University, St. Louis, MO 8:00 am—8:15 am The Use of a Microfluidic Invasion Network OP–Thurs–1–2 Room A312 Device (MIND) for Glioblastoma Prognosis and Response to Therapy Track: Biomaterials Bin Sheng Wong1, Sagar R. Shah2,3, Christopher Yankaskas1, Alfredo Quiñones-Hinojosa2, and Konstantinos Konstantopoulos1,3 3D Printing I 1The Johns Hopkins University, Baltimore, MD, 2Mayo Clinic, Chairs: Rosalyn Abbott, Jesse Placone Jacksonville, FL, 3The Johns Hopkins University School of Medicine, Baltimore, MD 8:00 am—8:15 am 3D Stereolithography Using Gelatin 8:15 am—8:30 am Methacrylate: A Novel Invasion Assay for Gene-expression Profiling of Patient-Derived Multicellular Aggregates Fibroblast and Breast Cancer Interactions Daniel Sazer1, Bagrap Grigoryan1, Jacob Albritton1, Amanda Avila1, Aparna Padhye2, Don Gibbons2, and Jordan Miller1 in a Three-Dimensional (3D) Organotypic 1Rice University, Houston, TX, 2The University of Texas MD Microfluidic Platform 1 1 2 1 Anderson Cancer Center, Houston, TX Danh Truong , Alexander Kratz , Jin G. Park , Eric S. Barrientos , Toan Nguyen1, Harpinder Saini1, Barbara A. Pockaj3, Ghassan Mouneimne4, and Mehdi Nikkhah1 1Arizona State University, Tempe, AZ, 2Biodesign Institute, Tempe, AZ, 3Mayo Clinic, Phoenix, AZ, 4University of Arizona, Tucson, AZ 4 BMES 2018 | Atlanta PLATFORM SESSIONS—THURSDAY—1—8:00 AM—9:30 AM AM—9:30 SESSIONS—THURSDAY—1—8:00 PLATFORM Thursday, October 18 | 8:00 am—9:30 am | Platform Session 1 8:30 am—8:45 am 8:45 am—9:00 am Leveraging Surface Plasmon Resonance Summary of 1599 Real World Head to Dissect the Interfacial Properties of Impacts in 45 American Football and Nanoparticles for Tumor Penetration Boxing Athletes Aniket Wadajkar1, Jimena Dancy1, Jeffrey Winkles1, Adam Bartsch1, Rajiv Dama1, Sergey Samorezov2, Jay Alberts2, Edward Graeme Woodworth1, and Anthony Kim1 Benzel2, Vincent Miele3, Alok Shah4, John Humm4, Michael McCrea4, 1University of Maryland School of Medicine, Baltimore, MD and Brian Stemper4 1Prevent Biometrics, Minneapolis, MN, 2Cleveland Clinic, Cleveland, 3 4 8:45 am—9:00 am OH, University of Pittsburgh Medical Center, Pittsburgh, PA, Medical College of Wisconsin & Zablocki VA Medical Center, Milwaukee, WI NK Cell-Based Immunotherapeutic Activity Against Anti-CD20Resistant Non-Hodgkin 9:00 am—9:15 am Lymphoma (NHL) in Microfluidic Droplets Pilot Field
Load more

Recommended publications
  • Congressional Record-House. January 11
    886 CONGRESSIONAL RECORD-HOUSE. JANUARY 11, CONFIRMATIONS. the Union Calendar, be referred back to that committee. Is there Executive nomination con.firmed by the Senate Decembe1· 20, 1.900. objection? [After a pause.] The Chair hears none. APPOINTMENT IN THE MARINE-HOSPITAL SERVICE. ACCOUNTS OF MARSHALS AND CLERKS OF DISTRICT COURTS IN THE TERRITORY OF UTAH. Benjamin S. Warren, of Alabama, to be an assis.tant surgeon in the Marine-Hospital Service of the United States. Mr. KING. Mr. Speaker, I ask unanimous consent for the present consideration of the bill (S. 5231) relating to the accounts Executive nominations con.firmed by the Senate Janua1'y 11, 1901. of United States marshals and clerks of the district courts of the UNITED STA.TES ATTORNEY. Territory of Utah. William G. Wheeler, of Wisconsin, to be attorney of the United _The SPEAKER. The gentleman from Utah asks unanimous States for the western district of Wisconsin. consent for the present consideration of the bill S. 5231, which is on the Speaker's table. POSTMASTER, The Clerk read as follows: David B. Rigdon, to be postmaster at Statesboro, Bu11och Be it enacted, etc., That the United States marshals and the clerks of the County, Ga. district courtg of the Territory of Utah prior to its admission to the Union as a State shall be held accountable only for fees earned in United States cases, in accordance with a decision of the Attorney-General dated Decem· · ber 2, 1891, and all unclosed accounts of such officers shall be settled and HOUSE OF REPRESENTATIVES. closed accordingly.
    [Show full text]
  • Biopolymeric Materials for Tissue Regeneration, Cell Manufacturing, and Drug Delivery
    University of Arkansas, Fayetteville ScholarWorks@UARK Theses and Dissertations 5-2021 Biopolymeric Materials for Tissue Regeneration, Cell Manufacturing, and Drug Delivery David Alfonso Castilla-Casadiego University of Arkansas, Fayetteville Follow this and additional works at: https://scholarworks.uark.edu/etd Part of the Polymer and Organic Materials Commons, and the Polymer Science Commons Citation Castilla-Casadiego, D. A. (2021). Biopolymeric Materials for Tissue Regeneration, Cell Manufacturing, and Drug Delivery. Theses and Dissertations Retrieved from https://scholarworks.uark.edu/etd/3964 This Dissertation is brought to you for free and open access by ScholarWorks@UARK. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of ScholarWorks@UARK. For more information, please contact [email protected]. Biopolymeric Materials for Tissue Regeneration, Cell Manufacturing, and Drug Delivery A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Engineering with a concentration in Chemical Engineering by David Alfonso Castilla-Casadiego Atlantic University Bachelor of Science in Chemical Engineering, 2011 University of Puerto Rico – Mayagüez Campus Master of Science in Chemical Engineering, 2016 May 2021 University of Arkansas This dissertation is approved for recommendation to the Graduate Council. ____________________________________ Jorge L. Almodóvar-Montañez, Ph.D. Dissertation Director ____________________________________ _________________________________
    [Show full text]
  • Boosting the Cellular Potency of Embryonic Stem Cells by Spliceosome Targeting ✉ Wilfried A
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans RESEARCH HIGHLIGHT OPEN Boosting the cellular potency of embryonic stem cells by spliceosome targeting ✉ Wilfried A. Kues1 Signal Transduction and Targeted Therapy (2021) 6:324; https://doi.org/10.1038/s41392-021-00743-9 In recent work published in Cell, Shen et al.1 identified transfected ES cells with short interfering RNAs against different spliceosome inhibition in embryonic stem (ES) cells as a key spliceosome transcripts (the spliceosome consisted of 5 core and mechanism for the transition from pluri- to totipotency. Spliceo- several cofactor subunits, here 14 transcripts were targeted), some inhibition, achieved by RNA interference or the chemical respectively. Transient repression of 10 of the 14 splicing factors inhibitor pladienolide B, may gain widespread relevance to the resulted in ES cells, which maintained the typical colony culture of totipotent ES cells, in vitro differentiation of extra- morphology, however, pluripotent marker genes—Oct4 (Pou5f1), embryonal tissue and organoids, translation to the maintenance of Nanog, Sox2, Zfp42 and others—became down-regulated, at the pluripotent cells of other mammal species, including humans, and same time marker genes of totipotency—particularly Zscan4s and a better molecular understanding of cellular potency in stem cells MERVL—were up-regulated. Zscan4s (Zink finger and SCAN and cancer. domain containing 4) is a transcription factor and MERVL (murine The first successful isolation and maintenance of ES derived endogenous retrovirus L) an endogenous retrovirus with a usually fi 1234567890();,: from the inner cell mass (ICM) of murine blastocyst stages was restricted expression to 2-cell embryos. These results were veri ed described in 1981,2 and since then acted as game changer for by supplementing the culture medium with pladienolide B, a genetic studies in this mammalian model organism.
    [Show full text]
  • Emanuele Giurisato Curriculum Vitae
    Emanuele Giurisato Curriculum Vitae Present position: Lecturer at University of Siena. Department of Biotechnology, Chemistry and Pharmacy, University of Siena. Via Aldo Moro, 1 53100, Siena, Italy Phone: +39 0577 232125 (office) e-mail: [email protected] Visiting scientist at University of Manchester Faculty of Biology, Medicine and Health Oxford Road, M13 9PT, Manchester, UK e-mail: [email protected] Education and training: 2014-2016 Marie-Curie Fellowship (I-MOVE 2013-1-OUT-24-EXP) University of Manchester 2009-present Lecturer at University of Siena 2008 Post-doctoral fellowship Department of Physiopathology Molecular Medicine and Public Health, University of Siena, Italy 2003-2007 Post-doctoral fellowship Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO (USA) 1999-2002 Ph.D student in “Molecular Medicine” Department of Physiopathology Molecular Medicine and Public Health, University of Siena, Italy 1996-1999 Research assistant, Department of Biomedical Experimental Sciences, CRIBI (University of Padua, Italy) 1996 BSc, Biological Sciences (specialization in Molecular Biology), Department of Biomedical Experimental Sciences, (University of Padua, Italy) Research experience: Nov.’96 -Sept. ‘99: Research assistant at the University of Padua, Department of Biomedical Experimental Sciences, CRIBI. Advisor: Dr. M. Cantini Telethon projects A101 “Myoblast-selective mitogens released by macrophage as a tool for muscle regeneration and gene therapy” and A095 “FasL engineered myoblasts can escape from death: requisite for immune protection in gene therapy via myoblast”. Oct.1999-Dec 2002: Ph. D. student in “Molecular Medicine” at the University of Siena. Advisor: Prof. A. Benedetti Research project: (i) role of plasma-membrane microdomains (rafts) in cellular responses to stimulatory molecules in T lymphocytes, (ii) Calcium signalling in T cells and (iii) involvement of lipid rafts during the immunological synapse formation.
    [Show full text]
  • Kent County Naturalization Name Index, Aalbers, A
    Kent County Naturalization Name Index Last name First name Middle name Volume Page Fir Sec Aalbers Aalbers V62 4 Aalbers Aalbert V24 141 Aalddriks Antonie V16 75 Aalderink John K. V16 355 Aaldrick Matthew V16 308 Aardem Arie V16 304 Aardema Klaas V17 27 Aarnouds Pieter V6 8 Aarnoudse Marenus V15 503 Abagis Chas V30 130 Abbas Sain Allez V49 265 Abbelma Joseph B1 F5 Abbelma Joseph V2 564 Abbott Frank V27 92 Abbott John V45 36 Abbott John V68 33 Abdella Salik V46 117 Abdo Ahamad V29 1 Abdoo Mike V41 168 Abeaf Moses V17 391 Abeaf Moses V17 394 Abel Frederick FW B1 F1 Abel Gustav B1 F4 Abel Gustav V2 540 Abel John W. V5 70 Abel Ludwig V8 134 Friday, January 19, 2001 Page 1 of 1325 Last name First name Middle name Volume Page Fir Sec Abella Salih V68 85 Abezi Albert V25 76 Aboabsee Theab V74 40 Aboasee Theab V18 150 Abood N. B1 F5 Abood Nemy V3 90 Abraham John V17 381 Abrahamson Charles Y. B7 200 Abram John B1 F1 Abramson Morris B1 F3 Abraursz Abram Peter V27 159 Abromaitis Louis V27 381 Abromaitis Louis V67 90 Absmaier Carl V77 4 Accardi Guiseppe V50 79 Acheson John V16 616 Achille Minciotti V51 142 Achtenhof Jakob V15 145 Achter Jan V17 200 Achterhof Henri B1 F1 Achterhof Johannes V15 500 Achterhof Matheus B1 F1 Achtjes John B7 107 Ackermann Joseph V15 282 Acton John C. B7 222 Adair David G. V15 335 Adair Joseph V15 335 Adalphson Emil V18 197 Friday, January 19, 2001 Page 2 of 1325 Last name First name Middle name Volume Page Fir Sec Adam Frickartz Heinrich V41 279 Adama Jelle V22 176 Adamawiczus Baltris V37 155 Adamczak Peter V38 245 Adamczyk Wladyslaw V35 291 Adams Edward John V24 70 Adams Frank B1 F2 Adams George W.
    [Show full text]
  • Engineering Lineage Potency and Plasticity of Stem Cells Using Epigenetic Molecules Received: 13 December 2017 Anandika Dhaliwal1, Sandra Pelka1, David S
    www.nature.com/scientificreports OPEN Engineering Lineage Potency and Plasticity of Stem Cells using Epigenetic Molecules Received: 13 December 2017 Anandika Dhaliwal1, Sandra Pelka1, David S. Gray1 & Prabhas V. Moghe 1,2 Accepted: 11 October 2018 Stem cells are considered as a multipotent regenerative source for diseased and dysfunctional Published: xx xx xxxx tissues. Despite the promise of stem cells, the inherent capacity of stem cells to convert to tissue- specifc lineages can present a major challenge to the use of stem cells for regenerative medicine. We hypothesized that epigenetic regulating molecules can modulate the stem cell’s developmental program, and thus potentially overcome the limited lineage diferentiation that human stem cells exhibit based on the source and processing of stem cells. In this study, we screened a library of 84 small molecule pharmacological agents indicated in nucleosomal modifcation and identifed a sub-set of specifc molecules that infuenced osteogenesis in human mesenchymal stem cells (hMSCs) while maintaining cell viability in-vitro. Pre-treatment with fve candidate hits, Gemcitabine, Decitabine, I-CBP112, Chidamide, and SIRT1/2 inhibitor IV, maximally enhanced osteogenesis in-vitro. In contrast, fve distinct molecules, 4-Iodo-SAHA, Scriptaid, AGK2, CI-amidine and Delphidine Chloride maximally inhibited osteogenesis. We then tested the role of these molecules on hMSCs derived from aged human donors and report that small epigenetic molecules, namely Gemcitabine and Chidamide, can signifcantly promote osteogenic diferentiation by 5.9- and 2.3-fold, respectively. Taken together, this study demonstrates new applications of identifed small molecule drugs for sensitively regulating the lineage plasticity fates of bone-marrow derived mesenchymal stem cells through modulating the epigenetic profle of the cells.
    [Show full text]
  • Cryptococcus Neoformans Thermotolerance to Avian Body Temperature Is Sufficient for Extracellular Growth but Not Intracellular S
    www.nature.com/scientificreports OPEN Cryptococcus neoformans Thermotolerance to Avian Body Temperature Is Sufficient Received: 30 October 2015 Accepted: 14 January 2016 For Extracellular Growth But Published: 17 February 2016 Not Intracellular Survival In Macrophages Simon A Johnston1,2, Kerstin Voelz3 & Robin C May3,4 Cryptococcus neoformans is a fatal fungal pathogen of humans that efficiently parasitises macrophages. Birds can be colonised by cryptococci and can transmit cryptococcosis to humans via inhalation of inoculated bird excreta. However, colonisation of birds appears to occur in the absence of symptomatic infection. Here, using a pure population of primary bird macrophages, we demonstrate a mechanism for this relationship. We find that bird macrophages are able to suppress the growth of cryptococci seen in mammalian cells despite C. neoformans being able to grow at bird body temperature, and are able to escape from bird macrophages by vomocytosis. A small subset of cryptococci are able to adapt to the inhibitory intracellular environment of bird macrophages, exhibiting a large cell phenotype that rescues growth suppression. Thus, restriction of intracellular growth combined with survival at bird body temperature explains the ability of birds to efficiently spreadC. neoformans in the environment whilst avoiding systemic disease. Cryptococcus neoformans is an environmental fungus that causes fatal human and animal disease. In humans, cryptococcosis causes hundreds of thousands of deaths each year, the vast majority in immunocompromised patients1. As with many significant pathogens, cryptococci are able to parasitise host cells. This potential for an intracellular lifestyle allows C. neoformans the potential to evade additional host immune responses and thus spread within the body, leading to systemic disease2,3.
    [Show full text]
  • Stem Cell Therapy and Gene Transfer for Regeneration
    Gene Therapy (2000) 7, 451–457 2000 Macmillan Publishers Ltd All rights reserved 0969-7128/00 $15.00 www.nature.com/gt MILLENNIUM REVIEW Stem cell therapy and gene transfer for regeneration T Asahara, C Kalka and JM Isner Cardiovascular Research and Medicine, St Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA, USA The committed stem and progenitor cells have been recently In this review, we discuss the promising gene therapy appli- isolated from various adult tissues, including hematopoietic cation of adult stem and progenitor cells in terms of mod- stem cell, neural stem cell, mesenchymal stem cell and ifying stem cell potency, altering organ property, accelerating endothelial progenitor cell. These adult stem cells have sev- regeneration and forming expressional organization. Gene eral advantages as compared with embryonic stem cells as Therapy (2000) 7, 451–457. their practical therapeutic application for tissue regeneration. Keywords: stem cell; gene therapy; regeneration; progenitor cell; differentiation Introduction poietic stem cells to blood cells. The determined stem cells differentiate into ‘committed progenitor cells’, which The availability of embryonic stem (ES) cell lines in mam- retain a limited capacity to replicate and phenotypic fate. malian species has greatly advanced the field of biologi- In the past decade, researchers have defined such com- cal research by enhancing our ability to manipulate the mitted stem or progenitor cells from various tissues, genome and by providing model systems to examine including bone marrow, peripheral blood, brain, liver cellular differentiation. ES cells, which are derived from and reproductive organs, in both adult animals and the inner mass of blastocysts or primordial germ cells, humans (Figure 1).
    [Show full text]
  • Outlist 2010
    Christopher Deal Bridget Hardy Gloria Leung Iris Ouyang Erica Shieh Brad Wergley Hiroshi Sasaki Viktor Kerney Jeremy Allen Elina Khodorkovsky Adam Wyatt Graduate Student, Master’s in Human Junior, Environmental Studies Freshman, Neuroscience Graduate Student, Linguistics Junior, Music Industry Senior, Cinema-Television Production Adjunct Assistant Professor, Masters Assistant Director for Student Leadership, Alumnus, B.A. in French, M.Ed. in PASA, Dedicated to LGBT youth that have taken Behavior (MHB) Program, Rossier School of Education Residential Education Alumnus, BA Fine Arts , 2010 Alumnus, B.A. International Relations and Anna Harley-Trochimczyk Ann Li Sara Parker Adam Siegel Marc Wetrich Tony Altimore Global Business, 2009 2004 Jackie DeLeon Senior, Chemical Engineering Junior, Business/IR Freshman, Business Administration in Graduate Student, Social Work Lisa Schweitzer Johnnathan Korver Alumnus, BS, 2001 Regina Lark Diane Yanez their own lives as a result of bullying, Sophomore, Film Production Alecs Harper Shuai Li Management Cinematic Arts Denice Wharton Associate Professor, School of Policy, Talent Acquisition Specialist, Career and Alumnus, Ph.D., 1999 Alumnus, Bachelors, Biology, 2006 Rebeca Delgado Sophomore, LNPS Graduate Student, Civil Engineering Aimee Sienkiewicz Senior, Political Science and Spanish Planning and Development Protective Services Cindy Ananias Sophomore, Writing for Film/Television Chris Passarelli Senior, Psychology Laura Isabel Serna Michael Kurland Alumnus, Health Promotion and Disease Radford Lathan harassment and campus homophobia. Keanna Harper Kevin Liang Senior, Political Science Gracie Wheelan Assistant Professor, School of Cinematic Academic Adviser, LAS College Prevention, 2009 Alumnus, Bachelor of Arts: Religion, Intl Campus Organization List Joshua DeMilta Sophomore, Business/Cinematic Arts Freshman, Biological Sciences Marie Paulo Erica Silva Senior, Critical Studies Arts, Critical Studies Debbie Ananias Relations, 2010 Sophomore, Broadcast Journalism Montana Harrington Alida Liberman Graduate Student, M.Ed.
    [Show full text]
  • Measurement of Hematopoietic Stem Cell Potency Prior to Transplantation
    WHITE PAPER Measurement of Hematopoietic Stem Cell Potency Prior to Transplantation February, 2009 This White Paper is a forward-looking statement. It represents the present state of the art and future technology in the field of stem cell potency testing. The views expressed in this White Paper are those of HemoGenix®, Inc. Changing the Paradigm Introduction The increased number of potential cellular therapies over recent years has necessitated stricter regulations to improve efficacy of the treatment and reduce risk to the patient. One of the regulations that was implemented by the European Medicines Agency (EMEA), Committee for Medicinal Products for Human Use (CHMP) on 15 May 2008 and the publication of a Draft Guidance by the United States Food and Drug Administration (FDA) in October 2008, was the requirement to measure the potency of a cellular product prior to administration to the patient. There have been two primary difficulties with these regulations. One of the difficulties encountered by the cellular therapy field is the understanding of what potency of a cellular product means. In the United States (U.S.), potency is actually defined in the Code of Federal Regulations (CFR) in Section 21, 600.3 “to mean the specific ability or capacity of the product, as indicated by appropriate laboratory tests or by adequately controlled clinical data obtained through the administration of the product in the manner intended, to effect a given result”. In the implemented EMEA “Guideline on potency testing of cell based immunotherapy medicinal products for the treatment of cancer”, potency is simply indicated as a “quantitative measure of biological activity” of the cell based immunotherapy product.
    [Show full text]
  • Research Highlights
    [CLIENT] Dittrich1611 NT1510146 3 March 2017 Research Highlights GOALS Search for the death record of Barbara Dittrich’s alleged twin, Anežka. Find the birth records of Barbara’s other siblings in the Kladno parish records. Continue to extend the ancestry of Barbara Dittrich in available Czech records. PROGRESS Determined that Barbora Anežka was not a twin. Though unusual for Bohemia, many children in Kladno at that time had middle names. Reexamined the client’s information about Barbora’s siblings, and noted the town Libušín was listed for two of their births. Libušín was part of the Smečno parish, and that it was right outside of Kladno. It now appears that the family moved from Kladno to Libušín between 1892 and 1894. Discovered Barbora’s younger sister Agnes/Anežka’s marriage record in Canada to Antony Kraus. Also discovered her death record, which listed a second husband and her birth in Libušin. According to the client’s information, she had married Antony Kraus and had sons named Tony and Joe. We found her gravestone, and that of two of her children, Joseph and Agnes. Attempted to search the Libušín birth records for Barbora’s siblings but discovered that the relevant parish registers for Smečno are not yet digitized. The relevant book, Smečno 42, was also not available onsite. Sent an email requesting a search of the Libušín birth records after 1900 at the Libušín vital records office. Searched the available Kladno birth records from 1865-1870 for the births of Barbora’s parents. Their births were not found, but several more Dittrich and Veselý siblings for both parents were discovered in the process.
    [Show full text]
  • Stem Cell Potency
    Stem Cell Potency By Rebecca Chan “Time is a circus, always packing up and moving away.” —Ben Hecht In a way, we never gave up trying to find that elixir of immortality. We try to better our lives or the way we live our lives because we have limited TIME. Stem cells are looked at as possible treatment to many diseases. These cells are bewildering because they share two properties: 1. Self-Renewal: the ability to undergo cell division and remain undifferentiated 2. Potency: the ability to differentiate to specialized cell types Toipotentcy A single totipotent cell is limitless and can divide and produce all differentiated cells of an organism into identical totipotent cells. Example: zygote, a fertilized egg cell. Humans emerge from that single totipotent cell. What was it like to have the ability to do anything? Were we ever given that chance? In kindergarten, we were asked what we wanted to be when we grew up. We were given anything to choose from, and there wasn’t any right or wrong answer. Scientist, astronaut, doctor, teacher, veterinarian, firefighter, and racecar driver were some of the answers given. When it came to me, I called out, “Everything.” I wanted to be everything. The teacher laughed and said, “Choose one.” I repeated, “Everything.” Why couldn’t I be everything? Barbie was everything and could do everything. Why not everything? The teacher gave me an odd look before she moved on. But the next guy’s answer wasn’t that far off from mine. “I want to be a superhero! A superhero, like Batman.” Pluripotency Pluripotency is the next level down from totipotency.
    [Show full text]